Laurus Labs

Who are the top shareholders of the Laurus Labs?

The top shareholders of Laurus Labs include M/s. Nsn Holdings (23.02%), foreign institutional investors (25.52%), mutual funds (6.88%), individual investors (23.65%), and New World Fund Inc (6.5%), with a pledged promoter holding of 2.6853%.

The top shareholders of Laurus Labs include a mix of institutional and individual investors. The largest shareholder is M/s. Nsn Holdings, represented by Dr. Satyanarayana Chava, holding 23.02%. Following that, foreign institutional investors (FIIs) collectively hold 25.52%, while mutual funds account for 6.88% through 29 different schemes. Individual investors own 23.65% of the company, and the highest public shareholder is New World Fund Inc, with a stake of 6.5%. Additionally, there is a pledged promoter holding of 2.6853%.

What does Laurus Labs do?

Laurus Labs Ltd is a fully integrated pharmaceutical and biotechnology manufacturing company, incorporated in 2005, with recent net sales of ₹1,720 Cr and a net profit of ₹234 Cr as of March 2025. It has a market cap of ₹34,563 Cr and key metrics include a P/E ratio of 97.00 and a dividend yield of 0.19%.

Overview: <BR>Laurus Labs Ltd is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Large Cap.<BR><BR>History: <BR>Laurus Labs was incorporated in the year 2005. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,720 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 234 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 34,563 Cr (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 97.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.19% <BR>Debt-Equity: 0.59 <BR>Return on Equity: 8.01% <BR>Price to Book: 7.73 <BR><BR>Contact Details: <BR>Address: Plot No 21 Jawaharlal Nehru, Pharma City Parawada Visakhapatnam Andhra Pradesh : 531021 <BR>Tel: 91-891-3061222 <BR>Email: secretarial@lauruslabs.com <BR>Website: http://www.lauruslabs.com

Has Laurus Labs declared dividend?

Laurus Labs has declared a 40% dividend, amounting to ₹0.8 per share, with an ex-date of May 9, 2025. The company has shown strong total returns over various periods, notably a 581.02% total return over the last 5 years.

Laurus Labs Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: 0.8<BR>- Ex-date: May-09-2025<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>Over the 6-month period, Laurus Labs experienced a price return of 7.42%, a dividend return of 0.14%, resulting in a total return of 7.56%.<BR><BR>In the 1-year period, the company saw a price return of 48.13%, a dividend return of 0.27%, leading to a total return of 48.4%.<BR><BR>For the 2-year period, Laurus Labs reported a price return of 85.48%, with a dividend return of 0.55%, culminating in a total return of 86.03%.<BR><BR>During the 3-year period, the price return was 15.04%, the dividend return was 0.89%, resulting in a total return of 15.93%.<BR><BR>In the 4-year period, the company achieved a price return of 16.03%, a dividend return of 0.89%, which led to a total return of 16.92%.<BR><BR>Over the 5-year period, Laurus Labs recorded a remarkable price return of 573.41%, with a dividend return of 7.61%, resulting in an impressive total return of 581.02%.<BR><BR>Overall, Laurus Labs has declared a substantial dividend, and the total returns over various periods indicate strong performance, particularly in the long term, highlighting the company's growth and shareholder value.

Who are the peers of the Laurus Labs?

Laurus Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ajanta Pharma, Piramal Pharma, Gland Pharma, J B Chemicals, and Cohance Life. Key insights show varying management risks, growth rates, and capital structures among these companies, with Divi's Lab leading in 1-year returns at 51.96% and Gland Pharma at the lowest with -11.87%.

Peers: The peers of Laurus Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ajanta Pharma, Piramal Pharma, Gland Pharma, J B Chemicals, and Cohance Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma and Cohance Life, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Gland Pharma, and J B Chemicals, and Average management risk is seen at Piramal Pharma. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is noted for Laurus Labs and J B Chemicals, and Below Average growth is present at Divi's Lab., Torrent Pharma, Ajanta Pharma, Gland Pharma, and Cohance Life. Excellent capital structure is attributed to Divi's Lab., Cipla, Dr Reddy's Labs, Ajanta Pharma, and Gland Pharma, while Good capital structure is seen at Torrent Pharma, Average capital structure is noted for Laurus Labs and Piramal Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Gland Pharma has the lowest at -11.87%. Laurus Labs' 1-year return is 44.38%, which is significantly higher than Gland Pharma's but lower than Divi's Lab.'s. Additionally, the peers with negative six-month returns include Piramal Pharma, Gland Pharma, and Cohance Life.

Who are in the management team of Laurus Labs?

As of March 2023, the management team of Laurus Labs includes M V G Rao (Chairman), CHAVA SATYANARAYANA (CEO), VENKATA RAVI KUMAR VANTARAM (CFO), and several independent directors. They oversee the company's strategic direction and operations.

As of March 2023, the management team of Laurus Labs includes the following individuals:<BR><BR>1. M V G Rao - Chairman & Independent Director<BR>2. CHAVA SATYANARAYANA - Executive Director & CEO<BR>3. VENKATA RAVI KUMAR VANTARAM - Executive Director & CFO<BR>4. Aruna Bhinge - Independent Non-Executive Director<BR>5. Rajesh Koshy Chandy - Independent Non-Executive Director<BR>6. Ravindranath Kancherla - Independent Non-Executive Director<BR>7. Venkata Lakshmana Rao Chunduru - Executive Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

How big is Laurus Labs?

As of 24th July, Laurus Labs Ltd has a market capitalization of 44,407.00 Cr, with Net Sales of 5,553.96 Cr and a Net Profit of 358.32 Cr for the latest four quarters. Shareholder's Funds are 4,472.56 Cr and Total Assets are valued at 9,335.57 Cr as of March 2025.

As of 24th July, Laurus Labs Ltd has a market capitalization of 44,407.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, Laurus Labs reported Net Sales of 5,553.96 Cr and a Net Profit of 358.32 Cr.<BR><BR>As of March 2025, the company's Shareholder's Funds stand at 4,472.56 Cr, while Total Assets are valued at 9,335.57 Cr.

When is the next results date for Laurus Labs?

The next results date for Laurus Labs is 23 October 2025.

The next results date for Laurus Labs is scheduled for 23 October 2025.

Is Laurus Labs technically bullish or bearish?

As of 20 October 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly indicators show mild bearishness and mixed signals from RSI readings.

As of 20 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum, while the weekly MACD and KST are mildly bearish, suggesting some caution. The monthly MACD remains bullish, and Bollinger Bands are bullish across both weekly and monthly time frames. However, the weekly RSI shows no signal and the monthly RSI is bearish, indicating mixed signals. Overall, the strength of the bullish stance is tempered by the mildly bearish indicators on the weekly charts.

How has been the historical performance of Laurus Labs?

Laurus Labs has shown fluctuating financial performance, with net sales increasing from 4,813.51 crore in March 2021 to 5,553.96 crore in March 2025, while profitability metrics like profit after tax declined from 983.82 crore to 354.41 crore in the same period. Despite significant growth in sales and total assets, the company has faced volatility in profitability and cash flow challenges.

Answer:<BR>The historical performance of Laurus Labs shows a fluctuating trend in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Laurus Labs' net sales increased from 4,813.51 crore in March 2021 to 5,553.96 crore in March 2025, despite a dip to 4,935.57 crore in March 2022 and a peak of 6,040.55 crore in March 2023. Total operating income followed a similar pattern, reaching 5,553.96 crore in March 2025. The company's total expenditure, excluding depreciation, rose from 2,267.17 crore in March 2020 to 4,498.68 crore in March 2025, reflecting increased operational costs. Operating profit (PBDIT) peaked at 1,598.19 crore in March 2023 but fell to 1,130.38 crore by March 2025. Profit before tax also saw fluctuations, peaking at 1,301.11 crore in March 2021 before declining to 484.29 crore in March 2025. Profit after tax followed a similar trend, with a high of 983.82 crore in March 2021 and a decrease to 354.41 crore in March 2025. The company's total assets grew from 3,676.39 crore in March 2020 to 9,335.57 crore in March 2025, while total liabilities increased from 1,935.94 crore to 2,693.08 crore in the same period. Cash flow from operating activities showed a decline from 993 crore in March 2023 to 601 crore in March 2025, indicating challenges in cash generation despite revenue growth. Overall, Laurus Labs has experienced significant growth in sales and assets, but profitability has faced volatility in recent years.

Is Laurus Labs overvalued or undervalued?

As of October 28, 2025, Laurus Labs is considered very expensive and overvalued with a PE ratio of 75.74, significantly higher than its peers, despite outperforming the Sensex with a year-to-date return of 59.32%.

As of 28 October 2025, the valuation grade for Laurus Labs has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued, with a PE ratio of 75.74, an EV to EBITDA of 45.57, and a PEG ratio of 0.18, which suggests that despite high earnings multiples, the growth expectations are not sufficiently justified by its financial performance.<BR><BR>In comparison to its peers, Laurus Labs stands out with a notably higher PE ratio than Sun Pharma Industries at 35.35 and Divi's Laboratories at 74.05, both of which are categorized as expensive or very expensive. Additionally, while Laurus Labs has a lower EV to EBITDA than Divi's, it still remains significantly above the industry average, reinforcing its overvaluation status. Notably, Laurus Labs has outperformed the Sensex in recent periods, with a year-to-date return of 59.32% compared to the Sensex's 8.30%, which may contribute to inflated expectations surrounding its valuation.

Are Laurus Labs Ltd latest results good or bad?

Laurus Labs Ltd's latest Q3 FY26 results are strong, with a net profit of ₹251.66 crore (up 172.65% year-on-year) and revenue of ₹1,778.29 crore (up 25.67%). The operating margin improved to 27.00%, marking the highest in eight quarters, indicating robust growth and operational efficiency.

Laurus Labs Ltd's latest results for Q3 FY26 are quite impressive, indicating a strong performance overall. The company reported a net profit of ₹251.66 crore, which represents a remarkable year-on-year increase of 172.65%. Additionally, revenue for the quarter reached ₹1,778.29 crore, marking a 25.67% growth compared to the same quarter last year.<BR><BR>The operating margin has also seen significant improvement, reaching 27.00%, which is the highest in the past eight quarters and up from 20.15% in Q3 FY25. This reflects enhanced operational efficiency and better capacity utilization.<BR><BR>Furthermore, the company's return on equity stands at a solid 16.67%, indicating strong capital efficiency. Overall, Laurus Labs is demonstrating robust growth and operational strength, making its latest results favorable.

Should I buy, sell or hold Laurus Labs Ltd?

Why is Laurus Labs Ltd falling/rising?

As of 16-Mar, Laurus Labs Ltd's stock price is falling, currently at 961.50, reflecting a 4.2% decrease. The stock has underperformed its sector and shows ongoing weakness, with significant declines over the past week and month, raising concerns about its long-term growth prospects.

As of 16-Mar, Laurus Labs Ltd's stock price is falling, currently at 961.50, which reflects a decrease of 42.15 (-4.2%). This decline is part of a broader trend, as the stock has underperformed its sector by 3.08% today and has experienced consecutive falls over the last two days, totaling an 8.07% drop in that period. <BR><BR>In terms of recent performance, the stock has seen a 5.82% decline over the past week and a 5.07% decline over the past month, indicating ongoing weakness. Additionally, the stock touched an intraday low of Rs 951.5, which is a significant drop of 5.2%. The weighted average price suggests that more volume was traded closer to this low price, further indicating bearish sentiment among investors.<BR><BR>Despite some positive factors such as high management efficiency and strong growth in net profit, the stock's long-term growth prospects appear poor, with net sales growing at an annual rate of only 9.65% and operating profit at 2.57% over the last five years. This has contributed to a perception of an expensive valuation, as indicated by a high enterprise value to capital employed ratio. <BR><BR>Overall, the combination of recent price declines, underperformance relative to benchmarks, and concerns about long-term growth prospects are contributing to the falling stock price of Laurus Labs Ltd.

Which are the latest news on Laurus Labs?